Cocrystal Pharma, Inc. (COCP)
- Previous Close
1.5200 - Open
1.5900 - Bid --
- Ask --
- Day's Range
1.5620 - 1.5900 - 52 Week Range
1.3300 - 3.2900 - Volume
739 - Avg. Volume
13,712 - Market Cap (intraday)
15.891M - Beta (5Y Monthly) 1.35
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8700 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
www.cocrystalpharma.comRecent News: COCP
Performance Overview: COCP
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: COCP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: COCP
Valuation Measures
Market Cap
15.89M
Enterprise Value
-8.61M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.60
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.41
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.68%
Return on Equity (ttm)
-54.54%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-17.98M
Diluted EPS (ttm)
-1.8700
Balance Sheet and Cash Flow
Total Cash (mrq)
26.35M
Total Debt/Equity (mrq)
7.02%
Levered Free Cash Flow (ttm)
-10.01M